Newsletter Signup x
Diffuse Midline Gliomas (DMGs) are aggressive childhood brain tumours, which include diffuse intrinsic pontine gliomas (DIPG). There is currently no cure. A class of cancer drugs, called MEK inhibitors, have shown early promise in treating some DMGs but there is a risk that these tumours could develop resistance to these drugs. Prof. Chris Jones and his team aim to work out the mechanisms by which DMG cells become resistant to MEK inhibitors and come up with new combination treatments to overcome this.
Evolutionary dynamics of MEK inhibitor sensitivity and resistance in diffuse midline glioma
Prof. Chris Jones
Institute of Cancer Research
Sutton, SM2 5NG
1 April 2021
30 months
£349,393
Refining our knowledge about the genetic causes of leukaemia
A large number of genetic mutations have been identified in childhood acute myeloid leukaemia (AML), with any one child having
Read morePatient Story – Georgia
Georgia was diagnosed with acute lymphoblastic leukaemia (ALL), a cancer of the blood, in 2008 when she
Read more